Key Highlights
● Returned to profit from a year-earlier loss
● Full-year Earnings and Cash Flow guidance raised
● Plans to separate retail pharmacy into an independent listed company
● Management calls next year a low point for Health Services
CVS Health Corporation (NYSE:CVS), one of the most widely followed names in the US healthcare sector, used its third-quarter report to deliver more than a set of earnings. The Woonsocket, Rhode Island, company reported higher revenue, swung from a net loss to a net profit, raised its full-year outlook for adjusted earnings and operating cash flow, and told investors on its conference call that it plans to separate into a pair of independent public companies. The results themselves arrived well ahead of the consensus figures cited in a pre-earnings preview, yet the separation plan quickly became the larger talking point.
Chairman and Chief Executive David Joyner said in the release that each Business delivered another quarter of strong results, and that the strategy centers on improving the consumer experience, lowering healthcare costs and connecting care. On the call, he framed the proposed split around a short list of benefits: focus, Capital allocation, agility and simplicity. He also rejected any suggestion of distress, pointing to a long run of quarters in which results beat expectations and guidance moved higher, along with progress on Debt reduction that came ahead of schedule.
Inside the Proposed Separation
Under the plan described on the call, the remaining CVS Health would contain Aetna, Caremark, specialty pharmacy, Oak Street Health and Signify Health, with Joyner continuing as chairman and chief executive. A newly independent CVS Pharmacy would contain the retail stores, mail order, MinuteClinic and a shared consumer platform that management expects to serve as a bridge between the companies. Prem Shah, currently a group president, is due to become chief executive of that retail business.
Management said completion is targeted for the first half of the year after next, subject to final board approval, the effectiveness of a registration statement and tax confirmation. The transaction is intended to be tax-free for US federal income tax purposes, and both companies are expected to carry investment-grade balance sheets. Chief Financial Officer Brian Newman said the process would take more than a year to complete. He also described the one-time and ongoing costs of disentangling the businesses as manageable, and said those costs would be offset over time, although the transcript does not show a detailed estimate of them.
One obvious question was whether a split would undo the integration that CVS assembled over many years. Market data noted that analysts asked about potential lost benefits from separating retail pharmacy and Caremark. Joyner responded that jointly developed products would be preserved through commercial agreements rather than an operating structure. Shah, for his part, noted that the retail pharmacy has operated behind a firewall from Caremark for many years, and argued that CVS Pharmacy can offer more services across its large store base.
The Headline Numbers, Described Without the Noise
According to the company's earnings release, total Revenue climbed from the prior-year period, with Health Services and Health Care Benefits doing most of the work. Operating results reversed from a loss to a profit. That swing owes a great deal to the comparison base, since the year-earlier quarter absorbed a very large Goodwill Impairment connected with the Health Care Delivery business, along with an opioid litigation charge and clinic closure costs, partly offset by a gain on the deconsolidation of Omnicare.
The cleaner comparison is adjusted operating income, which rose at a double-digit pace, and adjusted earnings per share, which also moved up sharply. The company attributed the adjusted earnings gain chiefly to Health Care Benefits and its Margin recovery plan. The latest quarter was not free of unusual items: it included a charge tied to Omnicare, recorded after a Bankruptcy court approved agreements resolving litigation and bankruptcy matters involving that former unit, as well as smaller Acquisition integration costs.
Market data in late October had set out a consensus for adjusted earnings and revenue that the reported figures comfortably exceeded. The same preview flagged that the whisper figure ran above consensus and that full-year consensus had appeared to lag the company's own guidance, suggesting that some estimates had not caught up with earlier raises.
Aetna's Margin Repair Keeps Advancing
Health Care Benefits, the segment containing Aetna, posted a modest revenue increase, but its profit improvement was far more pronounced. Adjusted Operating Income rose far above the year-earlier level, driven mainly by better underlying performance in government business. The medical benefit ratio, which measures the share of premium revenue consumed by medical claims, improved from the prior-year quarter, and the year-to-date ratio showed a similar improvement.
The revenue mix inside the segment is changing. Government premiums rose, while commercial premiums dropped, reflecting the company's exit from the individual exchange business this year. Medical membership was flat with the end of June and lower than a year earlier. The company also recorded favorable development of prior-year healthcare cost estimates over the year-to-date period, a detail worth noting when assessing how much of the improvement reflects current-period trends.
Aetna President Steven Nelson told analysts that Medicare Advantage is moving into profitable territory this year, ahead of expectations, though it remains on a multiyear path toward its intended margins. For next year, he listed benefit mix changes, geographic and product adjustments, network changes and stronger star ratings as the available levers, and he said early results from the annual enrollment period were unfolding as expected. The release added that a substantial majority of Aetna Medicare Advantage members are in highly rated plans for next year, a showing that places Aetna second among large publicly traded Medicare Advantage organizations.
Caution remained part of the message. Newman said the company is navigating elevated cost trends that remain above historical levels across the industry, although results were broadly in line with internal expectations. The release likewise described management as cautious for the remainder of the year, citing cost trends and possible macroeconomic headwinds.
Why Management Calls Next Year a Trough for Health Services
Health Services, home to the Caremark pharmacy benefit manager, generated the largest revenue in the group and posted strong top-line growth, helped by pharmacy drug mix and Brand Inflation and partly offset by continued price improvements for clients. Adjusted operating income edged up, and pharmacy claims processed increased modestly. Gross margin narrowed slightly, showing how revenue growth in this business does not necessarily translate into proportional profit.
The more consequential commentary concerned the year ahead. Management expects this segment's earnings to decline next year because of pressure in a federal drug discount program and lower Caremark membership stemming from client decisions, including Aetna's own standalone prescription drug plan book. Newman told analysts the company is confident that next year will reflect trough earnings for the segment, with growth expected to resume from there. Shah said the discount program is becoming a smaller part of segment earnings, though it will not disappear entirely.
This segment was already under scrutiny ahead of the report. The late-October preview noted that its outlook had merely been reiterated when other parts of the company were raised, and identified second-half softness, discount program pressure, client market exits and slightly weaker retention as issues investors were weighing. Against that backdrop, Shah pointed to a substantial Volume of gross new business won during the latest selling season and to expectations for a robust pipeline in a later season.
Pharmacy Volume Rises as Store Sales Soften
Pharmacy and Consumer Wellness presented a mixed picture. Revenue slipped from the prior-year quarter because of regulatory price cuts, generic introductions and reimbursement pressure, which outweighed drug mix, brand inflation and higher prescription volume. Yet adjusted operating income rose at a double-digit pace, supported by core pharmacy strength and contributions from Assets acquired from Rite Aid. Gross margin widened.
Same-store sales declined slightly at the total, pharmacy and front-store levels, while same-store prescription volume increased. Prescriptions filled rose modestly, helped by utilization and the Rite Aid files, though the absence of Omnicare long-term care volume acted as a drag. On the call, Shah said prescriptions for glucagon-like peptide therapies grew strongly, and that artificial intelligence now supports pharmacy workflow on the great majority of prescriptions. The release noted that CVS Pharmacy offers all such weight management products approved by US regulators through direct-to-consumer channels.
These trends matter more now that the retail business is headed toward independent life. Management guided the segment to low single-digit growth in adjusted operating income next year. As a standalone company, CVS Pharmacy would need to demonstrate that a large base of stores, combined with services such as MinuteClinic, can support earnings without direct ties to the insurance and pharmacy benefit operations.
Guidance, Cash and the Balance Sheet
For the full year, CVS raised its adjusted Earnings Per Share guidance to a new floor above the top of its previous range. The increase reflects Health Care Benefits and Pharmacy and Consumer Wellness. Cash flow from operations guidance rose by a wide margin, and the revenue outlook was presented as a minimum. The GAAP earnings guidance moved to a single floor that sits inside the former range rather than above it, showing how charges affect the reported figure differently from the adjusted measure.
Looking further ahead, Newman gave a preliminary floor for adjusted earnings per share next year, above the preliminary marker referenced in the October preview. He said this assumes only enough share repurchase activity to offset dilution, and that the company now expects to reach the high end of its compound adjusted earnings growth ambition through the year after next. Joyner declined to give guidance beyond that horizon.
The Balance Sheet offers some context for those plans. Cash and equivalents increased from the end of last year. So far this year, the company has repaid debt without issuing any new notes, and paid its regular dividends. Share repurchases are set to resume in the current quarter. Long-term debt remains substantial, which helps explain why management emphasized that both future companies are expected to be solid investment-grade issuers, with Newman adding that nothing is expected to impede future capital deployment.
The Year-to-Date Picture and the Reserve Signals
A broader frame for the quarter comes from the year-to-date figures. Revenue, GAAP earnings per share and adjusted earnings per share were all higher than in the same stretch of last year, when the company reported a GAAP loss per share. Operating Cash Flow more than doubled, which explains why management could lift its full-year cash flow guidance so substantially. The company's guidance suggests only limited further cash build in the final months, a pattern that fits with the way the new floor sits just above the amount already generated.
Insurance investors also look at claims reserves for signs of how conservatively a company is booking costs. Days claims payable edged up from the end of June but sat below the level of a year earlier. Within membership, commercial customers remain the largest group by a wide margin, followed by Medicare Advantage, Medicaid and Medicare Supplement. Those relative sizes help explain why Aetna's Medicare repricing can reshape margins even without large membership gains, since Nelson told analysts that a large share of the book is expected to have been repriced by the end of next year.
Prior actions continue to affect comparisons as well. Last year's figures included sizeable legacy litigation charges, most of them in the pharmacy segment, along with a loss on the wind-down and disposal of Accountable Care assets. The removal of those items flatters year-over-year reported growth, which is why the company and analysts tend to anchor on adjusted measures, while the reported figures remain the formal record.
Positioning Before the Report and What Remains Unanswered
Before the release, the preview described the stock as roughly level with the S&P 500 since the prior report and above its longer-term moving average, with bullish sentiment having cooled from a quarter earlier.
Several questions remain open. The transcript does not offer detailed estimates of separation costs or a final Capital Structure for either company, and completion depends on conditions including board approval and tax confirmation. Medical cost trends remain elevated, Medicare Advantage repricing is still in progress, and Caremark's expected trough has yet to play out. The next formal updates on those issues will come through later company reports and filings, as the separation work moves forward.



_11_19_2026_12_45_47_957380.jpg)
_11_19_2026_12_45_58_729375.jpg)

Please wait processing your request...